GNI Group Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
1,040
- Stock Symbol
-
2160
- Investments
-
15
- Share Price
-
$13.33
- (As of Friday Closing)
GNI Group General Information
Description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases. The company's business activities are divided into the pharmaceutical business and the medical device business. In the pharmaceutical business, the company conducts research and development, manufacturing, and sales of development compounds, mainly I-Suru, which is sold in the Chinese market, and F351, which has completed clinical trials. In the medical device business, the company develops, manufacture, and sell medical devices (biomaterials) based in the United States.
Contact Information
Website
www.gnipharma.comCorporate Office
- Nihonbashi-Honcho YS Building 3rd Floor
- 2-2-2 Nihonbashi-Honcho, Chuo-ku
- Tokyo, 103-0023
- Japan
Corporate Office
- Nihonbashi-Honcho YS Building 3rd Floor
- 2-2-2 Nihonbashi-Honcho, Chuo-ku
- Tokyo, 103-0023
- Japan
GNI Group Stock Performance
As of 13-Nov-2026, GNI Group’s stock price is $13.33. Its current market cap is $878M with 65.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.33 | $12.66 | $12.54 - $23.65 | $878M | 65.8M | 2.04M | -$0.64 |
GNI Group Financials Summary
As of 30-Jun-2026, GNI Group has a trailing 12-month revenue of $172M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 855,137 | 712,056 | 1,023,651 | 849,447 |
| Revenue | 171,780 | 179,331 | 155,901 | 185,115 |
| EBITDA | (3,452) | (15,534) | 15,807 | 97,504 |
| Net Income | (34,434) | (28,356) | 7,250 | 57,606 |
| Total Assets | 504,903 | 535,656 | 458,141 | 455,714 |
| Total Debt | 31,322 | 34,297 | 45,883 | 26,232 |
GNI Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GNI Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
GNI Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GNI Group Investments & Acquisitions (15)
GNI Group’s most recent deal was a Merger/Acquisition with AYUMI Pharmaceutical for . The deal was made on 01-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AYUMI Pharmaceutical | 01-Jul-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Zoo Labo | 09-Jan-2026 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Cullgen | 20-Nov-2023 | Secondary Transaction - Private | Drug Discovery | ||
| Shanghai Jiuce Medical Device Technology | 01-Aug-2023 | Merger/Acquisition | Surgical Devices | ||
| Cullgen | 13-Apr-2023 | Later Stage VC | Drug Discovery |
GNI Group ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.99 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
GNI Group Exits (5)
GNI Group’s most recent exit was on 20-Nov-2023 from Cullgen. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cullgen | 20-Nov-2023 | Completed |
|
||
| Cullgen | 13-Apr-2023 | Completed |
|
||
| Cullgen | 25-Feb-2021 | Completed |
|
||
| Reveal Biosciences | 02-Apr-2019 | Completed |
|
||
| Cullgen | 01-Mar-2018 | Seed Round | Completed |
GNI Group Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AYUMI Pharmaceutical | Tokyo, Japan | 2015 | |
| Shanghai Jiuce Medical Device Technology | Shanghai, China | 2014 | |
| Berkeley Advanced Biomaterials | Berkeley, CA | 1996 | |
| Zoo Labo | Kawasaki, Japan | 1989 |
GNI Group FAQs
-
When was GNI Group founded?
GNI Group was founded in 2001.
-
Where is GNI Group headquartered?
GNI Group is headquartered in Tokyo, Japan.
-
What is the size of GNI Group?
GNI Group has 1,040 total employees.
-
What industry is GNI Group in?
GNI Group’s primary industry is Drug Discovery.
-
Is GNI Group a private or public company?
GNI Group is a Public company.
-
What is GNI Group’s stock symbol?
The ticker symbol for GNI Group is 2160.
-
What is the current stock price of GNI Group?
As of 13-Nov-2026 the stock price of GNI Group is $13.33.
-
What is the current market cap of GNI Group?
The current market capitalization of GNI Group is $878M.
-
What is GNI Group’s current revenue?
The trailing twelve month revenue for GNI Group is $172M.
-
What is GNI Group’s annual earnings per share (EPS)?
GNI Group’s EPS for 12 months was -$0.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
